Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK Comparability of New vs Current Process Abatacept in Healthy Participants
NCT03714022Phase 1Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Nov 2018
- Primary completion
- Apr 2019
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of abatacept in rheumatoid arthritis (RA) (2 arms), sponsored by Bristol Myers Squibb. Primary endpoints: Maximum Observed Serum Concentration and Area Under the Curve to Infinity. Started Nov 2018; status: completed.
02
Drugs
abatacept
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT03714022.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03714022.